MedTrace Logo

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Characteristics of HHT120 in Healthy Subjects

NCT05414734 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-02-01

No results posted yet for this study

Summary

This is a first in human clinical trial with HHT120. The purpose of this study is to characterize the safety, pharmacokinetic (PK) and Pharmacodynamic (PD) profile of single and multiple twice-daily doses of HHT120 in healthy Subjects and to assess the effects of food on the PK profile of single-dose of HHT120 in healthy Subjects.

Conditions

  • Healthy

Interventions

DRUG

HHT120

Capsule, oral administration

DRUG

Placebo

Capsule, oral administration

Sponsors & Collaborators

  • Shanghai Synergy Pharmaceutical Sciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yiqing Zhao · Affiliated Hospital of Jiangnan University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-02-15
Completion
2023-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05414734 on ClinicalTrials.gov